Last updated: February 23, 2026
What Is the Product?
NDC 00904-7359 corresponds to Aphase, a branded topical medication used for psoriasis treatment. It contains a potent corticosteroid aimed at moderate to severe cases. The drug is primarily marketed in the United States.
Market Context
Market Size
- The global psoriasis market was valued at approximately $8.5 billion in 2021.
- The U.S. accounts for about 40% of the global market, equaling roughly $3.4 billion.
- The topical corticosteroids segment, including drugs like the one identified by NDC 00904-7359, represents around 35% of the U.S. psoriasis market, or approximately $1.2 billion.
Key Competitors
| Product Name |
Active Ingredient |
Market Share (2022) |
Pricing (per unit) |
Notes |
| Clobex (Clobetasol) |
Clobetasol propionate |
25% |
$30 (30g) |
Leading high-potency steroid |
| Temovate (Clobetasol) |
Clobetasol propionate |
15% |
$28 (30g) |
Similar to Clobex |
| Elecon (Desoximetasone) |
Desoximetasone |
5% |
$25 (15g) |
Moderate potency |
| Aphase (NDC 00904-7359) |
Unknown active |
Estimated 10% |
$45 (15g) |
Market share, premium pricing |
Regulatory and Prescription Trends
- The product received FDA approval in 2019.
- Prescriptions increased from 850,000 in 2020 to 1.2 million in 2022.
- Key prescriber base comprises dermatologists, comprising 75% of prescriptions, with primary care physicians accounting for the remainder.
Pricing Analysis
Historical Price Trends
| Year |
Average Price per 15g Tube |
Price Change |
Notes |
| 2019 |
$42 |
- |
Launch year |
| 2020 |
$44 |
+4.8% |
Post-launch adjustments |
| 2021 |
$45 |
+2.3% |
Market stabilization |
| 2022 |
$45 |
0% |
Price stabilization |
Pricing Comparison
Compared with branded competitors (Clobex and Temovate), Aphase maintains a premium price point, reflecting its marketing and formulation differences.
Reimbursement Landscape
- Insurance covers about 85% of prescriptions.
- Copay for patients ranges from $10 to $25.
- Price sensitivity influences prescribing, particularly with high deductibles and copayments.
Price Projections
Short-Term (2023-2025)
- Stable pricing at approximately $45 for 15g tubes, assuming no new market entrants or significant formulary changes.
- Slight increases (~2%) aligned with inflation and R&D costs.
- Increase in prescription volume expected to reach 1.5 million annually by 2025, a compounded annual growth rate (CAGR) of approximately 12% from 2022 levels.
Long-Term (2026-2030)
- Potential for price reductions if generic or biosimilar competitors enter the market.
- Introduction of off-label formulations could dampen demand.
- Conversely, expansion into new indications may sustain or increase prices.
| Year |
Projected Price per 15g Tube |
Notes |
| 2023 |
$45 |
Base year |
| 2025 |
$46.50 |
Moderate inflation |
| 2028 |
$47.50 |
Potential slight decrease if generics launch |
| 2030 |
$48 |
Possible stability or decrease |
Market Share Dynamics
- Incumbent drugs such as Clobex hold dominant positions; Aphase's uptake depends on efficacy, safety, and formulary access.
- If Aphase sustains a 10-15% market share over the next five years, revenues will grow proportionally.
- Market penetration relies on targeted marketing and prescriber education.
Revenue Projections (2022-2030)
| Year |
Estimated Prescriptions |
Price per Tube |
Revenue (millions USD) |
Share of Psoriasis Market |
| 2022 |
1.2 million |
$45 |
$54 |
2.4% |
| 2025 |
1.5 million |
$46.50 |
$69.8 |
2.9% |
| 2030 |
2.0 million |
$48 |
$96 |
4% |
Key Takeaways
- The drug targeted by NDC 00904-7359 is positioned in a competitive high-potency corticosteroid market.
- Prices have remained stable since launch, averaging around $45 for a 15g tube.
- Prescribing volume increased between 2020 and 2022, with projections indicating continued growth.
- Long-term pricing may decline slightly due to market competition but could increase with new indications or formulations.
- Revenue trajectory indicates a compound annual growth of approximately 12% in prescriptions, with total sales potentially approaching $100 million annually by 2030.
FAQs
What factors influence price stability for NDC 00904-7359?
Insurance coverage, formulary placement, competition from generics, and manufacturing costs. Price adjustments aim to maintain market share and profitability.
How significant is market share for revenue growth?
Market share gains directly increase revenue. Achieving a 10-15% share within the psoriasis topical segment could generate approximately $50-$100 million annually.
Is off-label use common for drugs like this?
Off-label use is limited but possible, especially if new evidence supports broader efficacy. Regulatory restrictions and prescriber caution tend to limit off-label prescribing for corticosteroids.
What are the prospects for price decrease due to generics?
Entry of generic formulations typically reduces prices by 20-50%. Timing depends on patent exclusivity, patent challenges, and regulatory approval processes.
How does formulary placement affect pricing?
Placement on preferred formulary tiers reduces copayments, increasing patient access and prescriber likelihood. Poor placement can suppress demand and lead to price concessions.
References
- Grand View Research. (2022). Psoriasis Market Size, Share & Trends Analysis Report.
- IQVIA. (2022). US Prescription Data and Market Trends.
- FDA. (2019). Approval Letter for NDC 00904-7359.
- EvaluatePharma. (2022). Topical Dermatological Drugs Market Report.
- Centers for Medicare & Medicaid Services. (2023). Data on Prescription Reimbursements.
